Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
September 19 2023 - 6:00AM
Business Wire
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq:
RPTX), a leading clinical-stage precision oncology company, today
announced it will present initial data from Module 1 and 2 of its
ongoing Phase 1 MYTHIC clinical trial in a plenary session at the
upcoming AACR-NCI-EORTC International Conference on Molecular
Targets and Cancer Therapeutics, being held October 11-15, 2023 in
Boston, MA. In addition to this presentation, the Company will
present multiple posters at the conference highlighting preclinical
and clinical developments, including data from Module 4 of its
Phase 1/2 TRESR clinical trial.
Module 1 and 2 of the Phase 1 MYTHIC clinical trial are
evaluating lunresertib (RP-6306), a first-in-class, oral PKMYT1
inhibitor alone and in combination with camonsertib
(RP-3500/RG6526), a potent and selective oral inhibitor of ATR,
while Module 4 of the Phase 1/2 TRESR trial is evaluating
camonsertib in combination with gemcitabine, both in molecularly
selected advanced solid tumors. Repare entered into a worldwide
license and collaboration agreement with Roche for the development
and commercialization of camonsertib.
Details for the plenary and poster presentations are as
follows:
Title: MYTHIC: First-in-human (FIH) biomarker-driven
phase I trial of PKMYT1 inhibitor lunresertib (lunre) alone and
with ATR inhibitor camonsertib (cam) in solid tumors with CCNE1
amplification or deleterious alterations in FBXW7 or PPP2R1A
Presenter: Dr. Timothy A. Yap, The University of Texas MD
Anderson Cancer Center, Houston, TX Abstract number: 35396
Poster number: B156 Session: Plenary Session 4: New
Drugs on the Horizon Session date and time: Friday, October
13 | 9:40 a.m. – 11:45 a.m. ET Session location: Level 3,
Ballroom AB
Title: Ataxia telangiectasia- and Rad3-related kinase
inhibitor (ATRi) camonsertib in combination with low dose
gemcitabine in patients with solid tumors with DNA damage response
(DDR) aberrations: Preclinical and Phase 1b results
Presenter: Dr. Ezra Rosen, Medical Oncology, Memorial Sloan
Kettering Cancer Center, New York, NY Poster number: B045
Session: Poster Session B Session date and time:
Friday, October 13 | 12:30 p.m. – 4:00 p.m. ET Session
location: Level 2, Exhibit Hall D
Title: Circulating tumor DNA (ctDNA) genomic and
epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage
repair (DDR) loss of function (LOF) and response monitoring in the
TRESR and ATTACC trials Presenter: Dr. Ezra Rosen, Medical
Oncology, Memorial Sloan Kettering Cancer Center, New York, NY
Poster number: A123 Session: Poster Session A
Session date and time: Thursday, October 12 | 12:30 p.m. –
4:00 p.m. ET Session location: Level 2, Exhibit Hall D
Title: Retrospective baseline biomarker analyses in a
first-in-human Phase 1 trial of the PKMYT1 inhibitor lunresertib
(RP-6306) in pts with advanced solid tumors harboring CCNE1
amplification and/or deleterious alterations in FBXW7 or PPP2R1A.
Presenter: Elia Aguado-Fraile, Repare Therapeutics Poster
number: B169 Session: Poster Session B Session date
and time: Friday, October 13 | 12:30 p.m. – 4:00 p.m. ET
Session location: Level 2, Exhibit Hall D
Title: Preclinical development of PKMYT1 and ATR
inhibitor combinations Presenter: Michael Zimmerman, Repare
Therapeutics Poster number: B057 Session: Poster
Session B Session date and time: Friday, October 13 | 12:30
p.m. – 4:00 p.m. ET Session location: Level 2, Exhibit Hall
D
Title: Preclinical development of PKMYT1 and WEE1
inhibitor combinations Presenter: David Gallo, Repare
Therapeutics Poster number: A023 Session: Poster
Session A Session date and time: Thursday, October 12 |
12:30 p.m. – 4:00 p.m. ET Session location: Level 2, Exhibit
Hall D
About Repare Therapeutics’ SNIPRx® Platform
Repare’s SNIPRx® platform is a genome-wide CRISPR-based
screening approach that utilizes proprietary isogenic cell lines to
identify novel and known synthetic lethal gene pairs and the
corresponding patients who are most likely to benefit from the
Company’s therapies based on the genetic profile of their tumors.
Repare’s platform enables the development of precision therapeutics
in patients whose tumors contain one or more genomic alterations
identified by SNIPRx® screening, in order to selectively target
those tumors in patients most likely to achieve clinical benefit
from resulting product candidates.
About Repare Therapeutics, Inc.
Repare Therapeutics is a leading clinical-stage precision
oncology company enabled by its proprietary synthetic lethality
approach to the discovery and development of novel therapeutics.
The Company utilizes its genome-wide, CRISPR-enabled SNIPRx®
platform to systematically discover and develop highly targeted
cancer therapies focused on genomic instability, including DNA
damage repair. The Company’s pipeline includes lunresertib (also
known as RP-6306), a PKMYT1 inhibitor currently in Phase 1 clinical
development; camonsertib (also known as RP-3500 or RG6526), a
potential leading ATR inhibitor currently in Phase 1/2 clinical
development and partnered with Roche; RP-3467, a preclinical Polθ
inhibitor program; as well as several additional, undisclosed
preclinical programs, including RP-1664. For more information,
please visit reparerx.com.
SNIPRx® is a registered trademark of Repare Therapeutics
Inc.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230919216180/en/
Repare: Steve Forte Executive Vice-President and Chief
Financial Officer Repare Therapeutics Inc.
investor@reparerx.com
Investors: Matthew DeYoung Argot Partners
repare@argotpartners.com
Media: David Rosen Argot Partners
david.rosen@argotpartners.com 212-600-1902
Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
From Jan 2025 to Feb 2025
Repare Therapeutics (NASDAQ:RPTX)
Historical Stock Chart
From Feb 2024 to Feb 2025